OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Eris Lifesciences OCF Yield % Related Terms
Eris Lifesciences OCF Yield % Historical Data
* Premium members only.
The historical data trend for Eris Lifesciences's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Eris Lifesciences's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eris Lifesciences OCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eris Lifesciences's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Eris Lifesciences's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eris Lifesciences (BOM:540596) has a OCF Yield % of 2.75 as of Jul. 04, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Eris Lifesciences and its competitors. Over the past decade, Eris Lifesciences' OCF Yield % has ranged from 2.75 to 2.75. According to the industry distribution chart, Eris Lifesciences ranks #549 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 54.5%.
Is Eris Lifesciences' OCF Yield % too high?
Eris Lifesciences' current OCF Yield % is 2.75. Over the past 10 years, this metric has ranged from a low of 2.75 to a high of 2.75. The Drug Manufacturers industry median OCF Yield % is 3.43. Eris Lifesciences' value of 2.75 is 19.8% below this industry median. Based on the distribution chart, Eris Lifesciences ranks #549 out of 1007 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Eris Lifesciences has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eris Lifesciences' OCF Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Eris Lifesciences ranks #549 out of 1007 companies for OCF Yield %. This places Eris Lifesciences in the lower half of its industry. The industry median OCF Yield % is 3.43. Eris Lifesciences' value of 2.75 is 19.8% below this benchmark. Historically, Eris Lifesciences' own OCF Yield % has ranged from 2.75 to 2.75 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Drug Manufacturers company?
The median OCF Yield % among Drug Manufacturers companies is 3.43, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eris Lifesciences's current OCF Yield % of 2.75 is 19.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Eris Lifesciences and its competitors. For the Drug Manufacturers industry, the median OCF Yield % is 3.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eris Lifesciences's current OCF Yield % is 2.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eris Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Eris Lifesciences (BOM:540596) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,647.71, compared to a current price of ₹1,432.00 — trading 13.1% below its estimated fair value. The current OCF Yield % is 2.75 and 19.8% below the Drug Manufacturers industry median of 3.43. Eris Lifesciences' overall GF Score™ is 91/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Eris Lifesciences (BOM:540596), the current OCF Yield % is 2.75 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eris Lifesciences (BOM:540596) Overvalued in 2026?
Based on GuruFocus' analysis, Eris Lifesciences stock appears to be undervalued.
The current stock price of ₹1,432.00 is trading 13.1% below its estimated GF Value™ of ₹1,647.71.
GuruFocus considers Eris Lifesciences to be Modestly Undervalued.
Key valuation signals for BOM:540596:
OCF Yield %: 2.75
GF Value™: ₹1,647.71 vs. price of ₹1,432.00 (13.1% below fair value)
Industry Position: 19.8% below the Drug Manufacturers median (#549 of 1007)
No single metric tells the full story. See the BOM:540596 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eris Lifesciences Ltd is an India-based company engaged in the manufacturing and sale of branded pharmaceutical formulations. It focuses on Lifestyle therapies such as Diabetes Care, Cardiac Care, Nutrition, Central Nervous System, and others. The company operates in a single segment that is pharmaceuticals. Some of its brands include Glimisave, Cyblex, Eritel, Atorsave and Crevast. The company works basically within India and International with the majority of revenue from India.
91GF Score
Get the complete analysis for BOM:540596
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540596 has been successfully added to your 
